Phase III_Parsaclisib and Ruxolitinib_Myelofibrosis_INCB 50465-313 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis